Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAM-002A in C9ORF72-Associated ALS
NCT05163886Phase 2Completed
- Sponsor
- OrphAI Therapeutics
- Start
- Dec 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apilimod in amyotrophic lateral sclerosis (ALS), sponsored by OrphAI Therapeutics. Started Dec 2021; status: completed.
02
Drugs
apilimod
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05163886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163886.